38.22
+0.7(+1.87%)
Currency In USD
Address
221 Crescent Street
Waltham, MA 02453
United States of America
Phone
650-394-5230
Sector
Healthcare
Industry
Biotechnology
Employees
196
First IPO Date
July 14, 2023
| Name | Title | Pay | Year Born |
| Dr. Michael Thomas Henderson M.D. | Chief Executive Officer & Director | 1.21M | 1990 |
| Ms. Jane Pritchett V. Henderson | Chief Financial Officer | 879,375 | 1966 |
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer | 879,375 | 1985 |
| Dr. Drew Badger Ph.D. | Senior Vice President and Head of Regulatory Affairs & Toxicology | 0 | N/A |
| Ms. Emily Cox | SVice President & Head of People | 0 | N/A |
| Ms. Wendy Aspden-Curran | Senior Vice President of Clinical Operations | 0 | N/A |
| Ms. Noel Kurdi | Vice President of Investor Relations | 0 | N/A |
| Ms. Monica Forbes | Senior Vice President of Finance | 0 | 1976 |
| Mr. Matthew Batters J.D. | Chief Legal Officer & Corporate Secretary | 0 | 1976 |
| Dr. Rebecca Dabora Ph.D. | Chief Development Officer | 0 | 1960 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.